VYNE Therapeutics Inc. 8K

Yarrow Bioscience outlined its reverse merger with VYNE Therapeutics to form Nasdaq-listed YARW and detailed plans to advance its anti-TSHR antibody YB-101 through Phase 2 in Graves’ Disease and thyroid eye disease, funded by about $200 million in capital and an expected cash runway into 2028.

Yarrow Bioscience, Inc. provided an investor presentation describing its planned reverse merger with VYNE Therapeutics Inc., under which the combined company is expected to begin trading on Nasdaq as YARW around July 24, 2026, with an estimated 97% post-closing ownership by Yarrow and its pre-closing financing investors; the presentation outlines Yarrow’s strategy to advance YB-101, a first-in-class anti-TSHR antibody in-licensed from Changchun GeneScience for Graves’ Disease and thyroid eye disease, supported by approximately $200 million of capital (including an expected $100 million pre-closing financing), Fast Track designation for its Graves’ program, ongoing Phase 1 studies in China by GenSci, a Phase 2a/2b Graves’ trial initiated in Q2 2026 with data anticipated in 2H 2027, and Yarrow’s expectation that its cash runway will fund operations into 2028 while VYNE stockholders receive a conditioned cash dividend estimated at $0.38 per share.

Filing Facts

CIK

1566044

Ticker

-

Form

8K

Source Type

sec

Accession

0001104659-26-083356

Alert Tier

7